A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 04 Sep 2018
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Aug 2018 Planned initiation date changed from 31 Jan 2018 to 30 Sep 2018.
- 24 Aug 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Dec 2017 Planned End Date changed from 30 Jun 2020 to 30 Jul 2020.